chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: headache; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the left arm on 20Mar2021 at 10:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was allergic with erythromycin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19 on an unknown date. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 22:45, 12 hours after receiving vaccine, the patient experienced headache that lasted through the night. Therapeutic measures were taken for the event headache and the treatment included 2 Tylenol 325 mg. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, SARS-CoV-2 test
Clinical narrative: headache; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6208) via an unspecified route of administration in the left arm on 20Mar2021 at 10:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient was allergic with erythromycin. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19 on an unknown date. Since the vaccination, the patient had not been tested for COVID-19. On 20Mar2021 at 22:45, 12 hours after receiving vaccine, the patient experienced headache that lasted through the night. Therapeutic measures were taken for the event headache and the treatment included 2 Tylenol 325 mg. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache was recovered on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymphadenopathy, Tenderness
Clinical narrative: Tender lymph node; the lymph node in my armpit of the same arm became swollen; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non pregnant female patient received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613); via unspecified route of administration in the right arm on 20Mar2021 (at the age 39-year-old) at 11:15 as single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure and Type II diabetes. The patient previously received trimethoprim-sulfamethoxazole (BACTRIM) for unspecified indication and experienced drug allergy. Concomitant medications included unspecified medicine prescribed to the patient. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 02:15, the patient reported lymph node in armpit of the right arm became swollen and tender. The patient did not receive any treatment for the reported events and chose to monitor. The patient had sent a note to PCP through patient portal so that the PCP was aware and could note in the patient's medical chart. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of swollen lymph node and tender lymph node was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymph node pain, Lymphadenopathy
Clinical narrative: Tender lymph node; the lymph node in my armpit of the same arm became swollen; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non pregnant female patient received first dose of BNT162b2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER2613); via unspecified route of administration in the right arm on 20Mar2021 (at the age 39-year-old) at 11:15 as single dose for COVID-19 immunisation. Medical history included asthma, high blood pressure and Type II diabetes. The patient previously received trimethoprim-sulfamethoxazole (BACTRIM) for unspecified indication and experienced drug allergy. Concomitant medications included unspecified medicine prescribed to the patient. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Mar2021 at 02:15, the patient reported lymph node in armpit of the right arm became swollen and tender. The patient did not receive any treatment for the reported events and chose to monitor. The patient had sent a note to PCP through patient portal so that the PCP was aware and could note in the patient's medical chart. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of swollen lymph node and tender lymph node was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate decreased, Heart rate increased, Tachycardia
Clinical narrative: Tachycardia; This is a spontaneous report from a contactable consumer, the patient.  A 37-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: not known) via unspecified route of administration in the left arm on 21Mar2021 at 08:30 (at the age of 37-years-old), as a single dose for COVID-19 immunisation.  Medical history included borderline mitral valve prolapse.  Past drug history included benzol peroxide to which patient developed allergy.  The patient did not receive any medication within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19.  On 21Mar2021 at 23:45, the patient experienced tachycardia 120-150 BPM, which continued for 11 hours.  The patient did not receive treatment for the reported event.  The clinical outcome of the event tachycardia was resolving.  Information about lot cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Heart rate, Tachycardia
Clinical narrative: Tachycardia; This is a spontaneous report from a contactable consumer, the patient.  A 37-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: not known) via unspecified route of administration in the left arm on 21Mar2021 at 08:30 (at the age of 37-years-old), as a single dose for COVID-19 immunisation.  Medical history included borderline mitral valve prolapse.  Past drug history included benzol peroxide to which patient developed allergy.  The patient did not receive any medication within two weeks prior to the COVID-19 vaccine. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19.  On 21Mar2021 at 23:45, the patient experienced tachycardia 120-150 BPM, which continued for 11 hours.  The patient did not receive treatment for the reported event.  The clinical outcome of the event tachycardia was resolving.  Information about lot cannot be obtained. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Herpes zoster
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Fatigue, Headache, Herpes zoster, Lymphadenopathy
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Musculoskeletal stiffness, Neck pain, Oropharyngeal pain, Pain, Pain in jaw
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pain of skin, Paraesthesia, Rash, Skin warm, Vomiting
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthralgia, Lymph node pain, Lymphadenopathy, Neck pain, Pain in jaw
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Paraesthesia, Rash erythematous
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6199), via an unspecified route of administration in the left arm on 18Mar2021 at 15:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included thyroid issues. Concomitant medications were not reported. The patient was allergic to penicillin and sulfa drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 18Mar2021 at 15:30, the patient experienced immediate tingling in arm, wrist and hand of left arm where vaccine was given. The jaw and neck pain was experienced on left side within 5 minutes of receiving vaccine. The pain continued in neck and moved to shoulder in evening. The lymph node on left side became swollen and painful. The red bumps on back of neck, back, shoulder area appeared by evening where vaccine was given. All the symptoms were on left side, which was the side vaccine was administered. On the second day, neck and shoulder pain persisted and bumps grew in size and quantity and continued to be painful. The lymph node continued to be swollen and sore to the touch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events tingling, jaw pain, neck pain, shoulder pain, swollen lymph node, lymph node pain and red rash was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal discomfort, Diarrhoea
Clinical narrative: Diarrhea for 36 hours; Upset stomach; This is a spontaneous report from a contactable consumer, the patient. A 41-years old non pregnant female patient received BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number; ER2613) via an unspecified route of administration to Left arm as unknown Single dose for COVID-19 immunisation on 19Mar2021 at 10:00 (at the age of 41 years). Medical history included multiple sclerosis, latex allergy, PCN allergy (penicillin), birth control. The patient received concomitant medication within 2 weeks of vaccination that included Betaseron (MANUFACTURER UNKNOWN), Wellbutrin(MANUFACTURER UNKNOWN), Ritalin (MANUFACTURER UNKNOWN) all unknown indications and dates. Prior to vaccination, patient was not diagnosed with COVID-19; Since the vaccination, patient was not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 19Mar2021 at 20:00, patient experienced diarrhoea for 36 hours and upset stomach for about 48 hours. The therapeutic measures were not given. The clinical outcome of the event diarrhoea (on 21Mar2021) and upset stomach (on 22Mar2021) were recovered.  No follow-up attempts are possible. No further information is expected.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Received back to back doses ofvaccine (estimated 0.45 mL); This is a spontaneous report from a non-contactable nurse. An 87-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: UNKNOWN) via an intramuscular on 12Mar2021 at 09:15 (at the age of 87-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient had medications within 2 weeks of vaccination. It was unknown whether the patient had received any other vaccines within 4 weeks prior to the vaccine. It was unknown whether the patient has tested for COVID-19, since the vaccination. On 12Mar2021 at 09:15, the patient received back-to-back doses of vaccine and administered an estimated 0.45 mL (incorrect dose of vaccine administered). Watched for 30 minutes without reaction noted. No therapeutic measures were not taken for the event. The clinical outcome of event, incorrect dose administered was unknown.   Information about lot number cannot be obtained. No further information is expected.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Received back to back doses ofvaccine (estimated 0.45 mL); This is a spontaneous report from a non-contactable nurse. An 87-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: UNKNOWN) via an intramuscular on 12Mar2021 at 09:15 (at the age of 87-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient had medications within 2 weeks of vaccination. It was unknown whether the patient had received any other vaccines within 4 weeks prior to the vaccine. It was unknown whether the patient has tested for COVID-19, since the vaccination. On 12Mar2021 at 09:15, the patient received back-to-back doses of vaccine and administered an estimated 0.45 mL (incorrect dose of vaccine administered). Watched for 30 minutes without reaction noted. No therapeutic measures were not taken for the event. The clinical outcome of event, incorrect dose administered was unknown.   Information about lot number cannot be obtained. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Discomfort, Erythema, Pruritus, Rash
Clinical narrative: Severely itchy and red skin on thefront neck; Severely itchy and red skin on thefront neck; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose BNT162b2 (PFIZER- BIONTECH COVID-19 m RNA vaccine, Lot number: ER8727), via an unspecified route of administration in the left arm on 21Mar2021 at 16:30 (at the age of 33-years-old), as a single dose for COVID-19 immunisation. Medical history included hypersensitive skin (dermographism). Concomitant medications included vitamin D (MANUFACRURER UNKNOWN) and vitamin B complex (MANUFACRURER UNKNOWN) all for unknown indications from unknown date. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 00:00, the patient experienced severely itchy and red skin on the front neck that started to occur during sleep (approximately 8 hours post vaccination). The patient did not receive any treatment for the reported events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events itchy skin and skin red were not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Erythema, Pruritus
Clinical narrative: Severely itchy and red skin on thefront neck; Severely itchy and red skin on thefront neck; This is a spontaneous report from a contactable consumer, the patient. A 33-year-old non-pregnant female patient received the first dose BNT162b2 (PFIZER- BIONTECH COVID-19 m RNA vaccine, Lot number: ER8727), via an unspecified route of administration in the left arm on 21Mar2021 at 16:30 (at the age of 33-years-old), as a single dose for COVID-19 immunisation. Medical history included hypersensitive skin (dermographism). Concomitant medications included vitamin D (MANUFACRURER UNKNOWN) and vitamin B complex (MANUFACRURER UNKNOWN) all for unknown indications from unknown date. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 22Mar2021 at 00:00, the patient experienced severely itchy and red skin on the front neck that started to occur during sleep (approximately 8 hours post vaccination). The patient did not receive any treatment for the reported events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events itchy skin and skin red were not resolved.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear haemorrhage, Ear pain, Ear swelling, Tenderness
Clinical narrative: Earache; swollen ear; spot bleeding; This is a spontaneous report from a contactable physician, the patient. A 36 -years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021at 08:00 (at the age of 36-years -old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and concomitant medication. The patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL9269) via an unspecified route of administration in the left arm on 27Feb2021at 09:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient had not tested for COVID-19. The patient not had any symptoms associated with COVID-19. The patient did not have allergies to medications, food, or other product. On 20Mar2021 at 20:00 the patient experienced earache, swollen ear and spot bleeding. The patient received Tylenol and diphenhydramine for the treatment of events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of earache, swollen ear, spot bleeding was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear pain, Ear swelling, Vaginal haemorrhage
Clinical narrative: Earache; swollen ear; spot bleeding; This is a spontaneous report from a contactable physician, the patient. A 36 -years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER2613) via an unspecified route of administration in the left arm on 20Mar2021at 08:00 (at the age of 36-years -old) as a single dose for COVID-19 immunisation. The patient did not have any medical history and concomitant medication. The patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EL9269) via an unspecified route of administration in the left arm on 27Feb2021at 09:30 (at the age of 36-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient had not tested for COVID-19. The patient not had any symptoms associated with COVID-19. The patient did not have allergies to medications, food, or other product. On 20Mar2021 at 20:00 the patient experienced earache, swollen ear and spot bleeding. The patient received Tylenol and diphenhydramine for the treatment of events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of earache, swollen ear, spot bleeding was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Diarrhoea, Oedema peripheral
Clinical narrative: Diarrhea; watery stool; swelling of left hand knuckles; pain in left hand knuckles and pain in joint on finger of right hand; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6202), via unspecified route administration in the left arm on 10Mar2021 at 13:15 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The medical history included breast cancer, fluid overload and congestive heart failure. The patient received second dose of shingles vaccine via unspecified route administration in left arm on 13Feb2021, within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested positive for COVID-19. Concomitant medication was not provided. The facility where the most recent COVID-19 vaccine was administered was at a pharmacy or drug store. On 12Mar2021, at 07:00, the patient experienced diarrhea, watery stool, swelling and pain of left-hand knuckles and pain in joint on finger of right hand. The clinical outcome of diarrhea, watery stool, joint swelling and pain in joint was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Arthralgia, Diarrhoea, Joint swelling
Clinical narrative: Diarrhea; watery stool; swelling of left hand knuckles; pain in left hand knuckles and pain in joint on finger of right hand; This is a spontaneous report from a contactable consumer, the patient. A 64-year-old non pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6202), via unspecified route administration in the left arm on 10Mar2021 at 13:15 (at the age of 64-years-old), as a single dose for COVID-19 immunisation. The medical history included breast cancer, fluid overload and congestive heart failure. The patient received second dose of shingles vaccine via unspecified route administration in left arm on 13Feb2021, within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested positive for COVID-19. Concomitant medication was not provided. The facility where the most recent COVID-19 vaccine was administered was at a pharmacy or drug store. On 12Mar2021, at 07:00, the patient experienced diarrhea, watery stool, swelling and pain of left-hand knuckles and pain in joint on finger of right hand. The clinical outcome of diarrhea, watery stool, joint swelling and pain in joint was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Axillary pain, Lymphadenopathy, Muscular weakness
Clinical narrative: This is a spontaneous report from healthcare professional, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the right arm on 20Mar2021 at 11:00 (at the age of 50-years-old), as a single dose for COVID-19 immunisation. Medical history included allergic to whey. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 20Mar2021, the patient experienced jabbing pain in the right armpit throughout night which was still ongoing and weakness in the right arm. The patient did not receive any treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events jabbing pain in the right armpit and weakness in the right arm were not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Axillary pain, Muscular weakness
Clinical narrative: This is a spontaneous report from healthcare professional, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the right arm on 20Mar2021 at 11:00 (at the age of 50-years-old), as a single dose for COVID-19 immunisation. Medical history included allergic to whey. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. On 20Mar2021, the patient experienced jabbing pain in the right armpit throughout night which was still ongoing and weakness in the right arm. The patient did not receive any treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events jabbing pain in the right armpit and weakness in the right arm were not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 26.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling hot, Nausea
Clinical narrative: Feeling hot; Nauseated; This is a spontaneous report from a healthcare professional. A 26-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6204) via intra muscular route of administration, on 06Mar2021, at 15:15, (at the age of 26-years-old), as a single dose for COVID-19 immunisation. Medical history included asthma and it was unknown if the patient was pregnant at the time of vaccination. The patient was allergic to latex (burns), triple antibiotic ointment (unspecified), divalproex (MANUFACTURER UNKNOWN), and prazosin (MANUFACTURER UNKNOWN). Concomitant medication was not reported. It was unknown if the patient received any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, it was unknown if the patient was diagnosed with COVID-19. Since the vaccination, it was unknown, if the patient had been tested for COVID-19. On 06Mar2021, at 15:30, the patient felt hot and nauseated after 25 minutes post vaccination. No treatment was received as a result of adverse events. The clinical outcome of events feeling hot and nauseated was recovered on an unspecified date in 2021.   No follow-up are attempts possible. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dry mouth, Heart rate increased, Hyperhidrosis
Clinical narrative: Dry mouth and sweats; Sweat; Heart rate elevated to around 133/135 bpm; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration in the left arm on 17Mar2021 at 16:45 (at the age of 36-year-old) as a single dose for COVID-19 Immunisation. The patient was allergic to vancomycin and no other medical history was reported. The patient received fish oil (MANUFACTURE UNKNOWN), vitamin D (MANUFACTURE UNKNOWN), vitamin B-12 (MANUFACTURE UNKNOWN) and NUTRAFOL within 2 weeks of vaccination as concomitant medications. The patient did not receive any other vaccine 4 weeks prior to the covid vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 17Mar2021 at 16:45, the patients heart rate elevated to around 133/135 beats per minute (bpm), dry mouth and sweats followed. Symptoms lasted around 30 minutes. Roughly 60 minutes after vaccine was administered, heart rate gradually decreased to around 100 bpm (with the help of breathing exercises). Another 20-30 minutes later, heart rate fell to around 84 bpm. The rest of the evening/night, heart rate steadied in the 70s. It was reported that normal heart rate while awake (between 62 and 65 bpm) followed the next day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of dry mouth, sweats, heart rate elevated were recovered on 17Mar2021.   Information about lot/batch number cannot be obtained. No further information expected.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dry mouth, Heart rate, Heart rate increased, Hyperhidrosis
Clinical narrative: Dry mouth and sweats; Sweat; Heart rate elevated to around 133/135 bpm; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: unknown), via an unspecified route of administration in the left arm on 17Mar2021 at 16:45 (at the age of 36-year-old) as a single dose for COVID-19 Immunisation. The patient was allergic to vancomycin and no other medical history was reported. The patient received fish oil (MANUFACTURE UNKNOWN), vitamin D (MANUFACTURE UNKNOWN), vitamin B-12 (MANUFACTURE UNKNOWN) and NUTRAFOL within 2 weeks of vaccination as concomitant medications. The patient did not receive any other vaccine 4 weeks prior to the covid vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 17Mar2021 at 16:45, the patients heart rate elevated to around 133/135 beats per minute (bpm), dry mouth and sweats followed. Symptoms lasted around 30 minutes. Roughly 60 minutes after vaccine was administered, heart rate gradually decreased to around 100 bpm (with the help of breathing exercises). Another 20-30 minutes later, heart rate fell to around 84 bpm. The rest of the evening/night, heart rate steadied in the 70s. It was reported that normal heart rate while awake (between 62 and 65 bpm) followed the next day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of dry mouth, sweats, heart rate elevated were recovered on 17Mar2021.   Information about lot/batch number cannot be obtained. No further information expected.
Age: 50.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Myalgia, Pain in extremity, Respiratory distress, Sluggishness, Wheezing
Clinical narrative: Having a minor respiratory issue where I could hear myself wheezing; Soreness around the site of the shot; Feeling tired; Muscle soreness; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: 6205), via an unknown route of administration in the left arm on 16Mar2021 at 15:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient included allergies. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included ZYRTEC. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 16Mar2021 at 22:00, the patient experienced some soreness around the vaccination site of the shot, felt really tired along with muscle soreness. At 23:30, the patient experienced a minor respiratory issue, where patient could hear wheezing. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the vaccination site pain, tiredness and muscle soreness was resolved on 18Mar2021 (All the symptoms disappeared after 36 hours); while that of the wheezing was resolved on 17Mar2021 (this lasted about 1 hour).  No follow-up attempts are possible. No further information is expected.
Age: 50.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Myalgia, Vaccination site pain, Wheezing
Clinical narrative: Having a minor respiratory issue where I could hear myself wheezing; Soreness around the site of the shot; Feeling tired; Muscle soreness; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: 6205), via an unknown route of administration in the left arm on 16Mar2021 at 15:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history of the patient included allergies. The patient did not have any allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications included ZYRTEC. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 16Mar2021 at 22:00, the patient experienced some soreness around the vaccination site of the shot, felt really tired along with muscle soreness. At 23:30, the patient experienced a minor respiratory issue, where patient could hear wheezing. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the vaccination site pain, tiredness and muscle soreness was resolved on 18Mar2021 (All the symptoms disappeared after 36 hours); while that of the wheezing was resolved on 17Mar2021 (this lasted about 1 hour).  No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anxiety, Decreased appetite, Diarrhoea, Ear discomfort, Ear pain
Clinical narrative: Constant louder tinnitus/ ear ringing; Inner ear pain; Ear fullness that will notgo away; Loss of appetite.; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route in left arm on 13Mar2021 at 15:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included hemochromatosis, CHEK2 mutation, gastroesophageal reflux disease (GERD), thyroid nodules, interstitial cystitis and allergies (dust, cats, mold). Concomitant medications received within two weeks of vaccination included women's daily vitamins, CBD Oil (MANUFACTURER UNKNOWN) and ADVIL all taken for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 13Mar2021 at 20:00, the patient experienced constant louder tinnitus/ear ringing, inner ear pain and ear fullness that will not go away. It started within hours of the vaccine, worsened and continued, also had ongoing loss of appetite. Therapeutic measures for the events included lipo-flavonoid. The outcome of constant louder tinnitus/ear ringing, inner ear pain, ear fullness that will not go away and loss of appetite was not recovered. No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Loss of personal independence in daily activities, Nausea, Pain, Sleep disorder
Clinical narrative: Constant louder tinnitus/ ear ringing; Inner ear pain; Ear fullness that will notgo away; Loss of appetite.; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199) via an unspecified route in left arm on 13Mar2021 at 15:00 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included hemochromatosis, CHEK2 mutation, gastroesophageal reflux disease (GERD), thyroid nodules, interstitial cystitis and allergies (dust, cats, mold). Concomitant medications received within two weeks of vaccination included women's daily vitamins, CBD Oil (MANUFACTURER UNKNOWN) and ADVIL all taken for unknown indication. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. On 13Mar2021 at 20:00, the patient experienced constant louder tinnitus/ear ringing, inner ear pain and ear fullness that will not go away. It started within hours of the vaccine, worsened and continued, also had ongoing loss of appetite. Therapeutic measures for the events included lipo-flavonoid. The outcome of constant louder tinnitus/ear ringing, inner ear pain, ear fullness that will not go away and loss of appetite was not recovered. No follow-up attempts are needed. No further information is expected.